A SUPPLEMENT TO VOL. 33 SUPPL. 8
POMALYST® (pomalidomide) as
a Treatment Option for Patients
With Relapsed/Refractory Multiple Myeloma
SAAD Z. USMANI, MD, FACP
Director of Plasma Cell Disorders Program
Director of Clinical Research in Hematologic Malignancies
Levine Cancer Institute/Carolinas Healthcare System
Clinical Professor of Medicine
UNC-Chapel Hill School of Medicine
Charlotte, North Carolina
This promotional program was developed by Celgene Corporation with input
from Saad Z. Usmani, MD, FACP.
Dr. Usmani received a fee for his
participation in this program.
CHALLENGES IN RELAPSED/
REFRACTORY MULTIPLE MYELOMA
Multiple myeloma is characterized
by multiple periods of response,
M-protein levels.1 As M-protein levels
begin to rise, symptoms and active
Due to the inability to completely
eradicate residual myeloma cells,
relapse is inevitable, making
prolonging the duration of remission
an important goal of therapy for
myeloma.1,2 The cycle of response,
remission, and relapse poses clinical
challenges in multiple myeloma.1,4
Patients with relapsed/refractory
disease remain difficult to treat given
that they are typically symptomatic,
POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for patients
with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome
inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
IMPORTANT SAFETY INFORMATION
WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM
• POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known
human teratogen that causes severe birth defects or embryo-fetal death. In females of reproductive poten-
tial, obtain 2 negative pregnancy tests before starting POMALYST treatment.
• Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after stopping POMALYST treatment.
POMALYST is only available through a restricted distribution program called POMALYST REMS®.
Venous and Arterial Thromboembolism
• Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients
with multiple myeloma treated with POMALYST. Prophylactic antithrombotic measures were employed in
clinical trials. Thromboprophylaxis is recommended, and the choice of regimen should be based on assess-
ment of the patient’s underlying risk factors.
Please see Important Safety Information on pages 1S to 6S. Please see Brief Summary
of the full Prescribing Information, including Boxed WARNINGS, on pages 7S–11S.
This supplement is sponsored by Celgene Corporation.